Navigation Links
Immunovative Therapies Ltd. Introduces a Revolutionary Approach To Cancer Treatment
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire-iReach/ -- The most promising way to develop curative treatment that eliminates every cancer cell in a patient, says Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., would be by vaccinating the patient against the tumor.  The patient's own immune system, if correctly stimulated and manipulated, is capable of killing every last cancer cell. The concept of vaccine-based immune treatment of cancer is based on the body's own natural defense mechanism, which guards it against many diseases.  Vaccine immunotherapy has been shown to be an extremely effective treatment strategy for prevention of numerous potentially lethal infectious diseases.

Vaccines consisting of either killed or attenuated pathogens have revolutionized the public health system by thwarting the progression of many deadly infectious diseases, such as smallpox, poliomyelitis, rabies, diphtheria, cholera, typhoid fever, bubonic plague, measles, mumps, tetanus, and hepatitis B. Dr. Michael Har-Noy believes that the application of vaccination based therapy to cancer could similarly revolutionize cancer therapy.

However, Dr. Michael Har-Noy of Immunovative Therapies indicates that synthesizing effective cancer vaccines has proven to be much more difficult than developing vaccines for prevention of infectious diseases. Attempts to create successful immunotherapies in the form of cancer vaccines, despite decades of research and experimental trials, have yet to demonstrate significant curative potential in patients with malignant tumors.

The one dramatic exception to the failure of immunotherapy to produce significant tumor killing effects in cancer patients is the immunologic response that occurs in patients undergoing allogenic bone marrow/stem cell transplantation (BMT). The BMT is a proven curative therapy for certain hematological malignancies and also has shown some effectiveness in the treatment of solid tumors. The curative effect of the BMT is caused by the transplanted immune cells, which are derived from a healthy, tissue matched donor. The immune mediated anti-tumor activity of these transplanted cells is termed the graft vs. tumor (GVT) effect. At Immunovative Therapies, this mechanism has been analyzed in detail, and Immunovative Therapies has used the powerful cancer-killing GVT effect as the basis for the synthesis of an entirely new class of oncologic drugs.

Dr. Michael Har-Noy describes the GVT mechanism as the most powerful and most efficient tumor-killing process ever identified in the treatment of human cancer. Unfortunately, these same immune system T-cells which control the GVT effect also can cause an often lethal complication known as graft versus host disease (GVHD). This side effect occurs because the transplanted T-cells recognize both the normal and tumor cells of the recipient as foreign material and attack them both indiscriminately. Therefore, despite the fact that a BMT can eradicate solid as well as hematologic cancers, the often lethal toxicity of GVHD has prevented the wide spread application of BMT as a cancer treatment.

The powerful GVT immune mechanism observed in BMT recipients is capable of disabling a tumor's immunoavoidance capability, thus resulting in complete eradication of the cancer in many instances. The GVT effect has been shown to be able to cure cancer patients with large tumors, including patients with malignancies unresponsive to chemotherapy, radiation and other types of immunologic treatments.

Immunovative Therapies has developed a line of biologic products, based upon completely proprietary technology, which is engineered to produce, in a cancer patient, the same anti-tumor effect that has been shown to be curative in allogenic bone marrow transplant (BMT) procedures but without the potentially lethal toxicity associated with it. Dr. Michael Har-Noy of Immunovative Therapies hopes to soon begin a Phase II/III trial of these drugs in metastatic breast cancer patients.

About: Immunovative Therapies Ltd. is a biotech company in Israel. Under the direction of its founder and CEO, Dr. Michael Har-Noy, the company is developing and testing revolutionary new cancer treatments that, when brought to market, will likely spawn a new field of oncology.

Media Contact: Bethany Franklin, Optimizeup.com, 1-800-701-6787, support@optimizeup.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Immunovative Therapies Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
(Date:6/22/2016)... ANGELES , June 22, 2016   StockNewsNow.com ... SNNLive Video Interview with Dr. Nader Pourhassan , ... biotechnology company focused on the clinical development and potential ... prevention of HIV infection, according to the company,s website ... recorded on Tuesday, June 7 th , 2016, at ...
(Date:6/22/2016)... 22, 2016   ViaCyte, Inc. , a privately-held ... islet replacement therapy for the treatment of diabetes in ... Annual Meeting.  ISSCR 2016, the Global Stem Cell Event, ... West in San Francisco.    ... as follows:Event: , Focus Session: Tools for Basic and ...
(Date:6/22/2016)... Dallas, Texas (PRWEB) , ... June 22, 2016 ... ... ceremony aimed at placing a spotlight on immigrant achievements and contributions to North ... this year’s most important contributors from the immigrant community to the civic and ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):